RTI Surgical® Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, announced a new agreement with Oxford Performance Materials, Inc. (OPM), a pioneer in advanced materials and additive manufacturing (3-D printing) for biomedical applications.
The agreement grants RTI an exclusive license to OPM’s OsteoFab® technology platform for spinal applications in all U.S. markets. OsteoFab is a next-generation implant manufacturing process that builds implantable medical devices, layer-by- layer, using only laser light and OPM’s OXPEKK® polymer. The OsteoFab process and OXPEKK material combine to create implants that are designed to enable bone ongrowth.
OXPEKK is a proprietary high-performance biocompatible polymer formulation from OPM, designed for medical applications. This strong, pure, radiolucent, hydrophilic, load-bearing material boasts a successful history in orthopedic implant applications.
Under the agreement, OPM will manufacture RTI’s spinal implant designs using OsteoFab technology, and RTI will oversee finishing steps, packaging, marketing and distribution of finished products.
“We are thrilled to announce this agreement with Oxford Performance Materials,” said Brian K. Hutchison, president and CEO of RTI Surgical. “OsteoFab is an incredibly exciting technology that creates new opportunities for innovation in the spinal implant market. We look forward to working with OPM to offer our customers and their patients a new alternative for spinal implants.”
“We see RTI Surgical as a growth company in the spinal implant space,” said Scott DeFelice, chairman and CEO of OPM. “RTI is a leading developer of medical implants with a long history of putting sound science behind their products. From the outset, RTI has worked closely with us and we look forward to a lengthy and productive relationship that leverages the unique benefits of OsteoFab technology to improve patient care.”
For more information, visit: www.rtix.com